BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 16, 2014
View Archived Issues
Preclinical safety of [18F]FBYBF-2 validates dosimetric studies in humans
Read More
Sterna Biologicals presents first-in-class GATA-3-targeting DNAzymes
Read More
Preclinical and clinical data reported for PI3K-alpha kinase inhibitor in various cancers
Read More
Merck Serono and MorphoSys collaborate on immune-oncology
Read More
Horizon Discovery licenses CRISPR gene editing system
Read More
CQDM and Sanofi Canada form drug discovery partnership
Read More
Hyperion Therapeutics acquires Andromeda Biotech
Read More
AnGes signs agreement with Quintiles for phase III study of Collategene
Read More
Circassia discloses positive data from phase IIb dust mite allergy trial
Read More
ViiV Healthcare and Janssen to develop single-tablet regimen for HIV
Read More
FDA removes clinical hold on imetelstat myelofibrosis trial
Read More
Oncobiologics begins phase I trial of biosimilar ONS-3010
Read More
Bayer Schering Pharma discloses novel Mnk1 inhibitors
Read More
Parion and Santen sign option agreement for P-321 in Asia
Read More
EntreMed changes name
Read More
Phase I results on OPB-51602 in relapsed/refractory hematological malignancies
Read More
Boehringer Ingelheim patents BRD4 inhibitors
Read More
Esteve patent describes novel sigma1 receptor ligands
Read More
Merck & Co. prepares and tests novel PDE10A inhibitors
Read More
OncoMed halts enrollment and dosing in phase I trials of vantictumab and Fzd8-Fc
Read More
FDA approves Lymphoseek for use in head and neck cancer
Read More
Roche presents new TRPA1 antagonists
Read More
Celgene exercises option to license AG-221 under Agios collaboration
Read More
KalGene to collaborate with multiple organizations on biomarker and treatment for aggressive cancers
Read More
Phase IIb trial of CRS-207 and GVAX Pancreas vaccines opens for recruiting
Read More